Welcome to our dedicated page for Harpoon Therapeutics news (Ticker: HARP), a resource for investors and traders seeking the latest updates and insights on Harpoon Therapeutics stock.
Harpoon Therapeutics (HARP) is a clinical-stage biotech company pioneering T-cell redirecting treatments for cancer. This page provides investors and researchers with essential updates on clinical developments, research breakthroughs, and strategic partnerships.
Access timely press releases covering trial milestones, regulatory filings, and scientific publications. Our curated news collection enables informed tracking of HARP’s tri-specific platform progress and immuno-oncology pipeline advancements.
Key updates include therapeutic candidate developments, intellectual property announcements, and collaboration news with leading research institutions. All content is verified through primary sources to ensure accuracy.
Bookmark this page for centralized access to HARP’s latest advancements in protein engineering and cancer immunotherapy. Check regularly for objective updates on clinical programs and scientific discoveries.
Seismic Therapeutic, a machine learning immunology company, has appointed Julie Eastland as an Independent Director to its Board. Ms. Eastland brings over 30 years of experience in finance and strategy within clinical stage biotechnology companies. Her expertise spans the drug development process, from discovery to commercialization, particularly in oncology and immunology.
Ms. Eastland most recently served as CEO and Board Director of Harpoon Therapeutics (HARP), which was acquired by Merck & Co in March 2024. She has held various C-level executive roles in both private and public companies, including ReCode Therapeutics, Rainier Therapeutics, and Cascadian Therapeutics. Her experience includes guiding biotechnology companies through significant organizational growth and navigating financial and operational challenges.
FAQ
What is the market cap of Harpoon Therapeutics (HARP)?
